Adding Nivolumab Plus Ipilimumab to Chemo Improves OS in NSCLC
According to findings from an open-label, phase 3 trial, adding combination nivolumab-ipilimumab to chemotherapy improves overall survival (OS) over chemotherapy alone in patients with non–small-cell lung cancer (NSCLC; Lancet Oncol. 2021;22[2]:198-211).
“First-line nivolumab plus ipilimumab has shown improved [OS] in patients with advanced [NSCLC]. We aimed to investigate whether the addition of a limited course (two cycles) of chemotherapy to this combination would further enhance the clinical benefit,” explained Luis Paz-Ares, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain, and colleagues.
The trial took place across 103 hospitals in 19 countries; eligible patients included those 18 years or older with treatment-naive, histologically confirmed stage IV or recurrent NSCLC, and an Eastern Cooperative Oncology Group performance status of 0-1. Patients were randomized in a 1:1 ratio to receive platinum doublet chemotherapy (every 3 weeks; 4 cycles, control group; 2 cycles, experimental group) alone or with nivolumab (360 mg, received intravenously every 3 weeks) plus ipilimumab (1 mg/kg, received intravenously every 6 weeks).
The primary end point was OS. Randomization was arranged by tumor histology, sex, and PD-LI expression. Researchers also analyzed safety in all treated patients.
A total of 1150 patients were enrolled, with 719 (62.5%) randomly assigned to receive nivolumab plus ipilimumab with chemotherapy. At the time of the interim analysis (median follow up 9.7 months), the median OS in the experimental group was 14.1 months (95% CI, 13.2-16.2) and increased to 15.6 months (95% CI, 13.9-20.0) at the next follow-up (median 13.2 months). Alternatively, the control group saw a median OS of 10.7 months (95% CI, 9.5-12.4), which increased slightly to a median of 10.9 months (95% CI, 9.5-12.6) at the second follow-up.
Adverse events (AEs) of grade 3 or higher included neutropenia (in 24 patients in the experimental group vs 32 in the control group), anemia (21 vs 50), diarrhea (14 vs 2), increased lipase (22 vs 3), and asthenia (3 vs 8).
“Nivolumab plus ipilimumab with two cycles of chemotherapy provided a significant improvement in [OS] versus chemotherapy alone and had a favorable risk-benefit profile. These data support this regimen as a new first-line treatment option for patients with advanced NSCLC,” concluded Dr Paz-Ares et al.—Alexandra Graziano


